Helper-independent, L-selectin(low) CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5738-5749

  Peng, L ^a   Kjaergaard, J ^a   Plautz, G E ^a   Weng, D E ^a   Shu, S ^a   Cohen, P A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; L SELECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FIBROSARCOMA; HELPER CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; LUNG METASTASIS; LUNG TUMOR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH;

EID: 0034669969     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5738     Document Type: Article

References (59)

1. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules
2. Tumor antigens are constitutively presented in the draining lymph nodes
3. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
4. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
5. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
6. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
7. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors
8. Role of T cell subsets in tumor immunity
9. + T Cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
10. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells
11. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
12. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
13. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
14. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
15. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
16. Treatment of subcutaneous tumor with adoptively transferred T cells
17. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression
18. - helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon γ
19. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells
20. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
21. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
22. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
23. + T cell help
24. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
25. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
26. Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells
27. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors
28. + cytotoxic T lymphocytes express IL- 1 receptors and require IL-1 for secretion of IL-2
29. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory
30. + primary T helper cells: Role of IL-1 and IL-6 in inducing IL-2 secretion and subsequent proliferation
31. + T helper cell function in AIDS
32. + T helper cells
33. Recognition requirements for the activation, differentiation and function of T-helper cells specific for class I MHC alloantigens
34. + T cells to H-2Kb mutant (Kbm) determinants and the appearance of thymic influence on anti-Kbm CTL responsiveness
35. + T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
36. + T cell- and IL-2-dependent mechanism
37. + T-helper and a T-killer cell
38. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen
39. Requirements for T cell recognition and elimination of retrovirally-transformed cells
40. + T cell reactivity to a model tumor antigen
41. + T cell-dependent
42. Studies on the minimum requirements for in vitro 'cure' of tumor cells by cytotoxic T lymphocytes
43. Local T helper cell signals by lymphocytes infiltrating intraocular tumors
44. Characterization of specific T helper cell activity in mice bearing alloantigenic tumors in the anterior chamber of the eye
45. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
46. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL
47. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
48. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: Correlation with clonal IL 2 receptor expression
49. Propagation of murine and human T cells with defined antigen specificity and function
50. Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors
51. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
52. Costimulatory regulation of T cell function
53. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro
54. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro
55. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells
56. + T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens
57. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells
58. Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells
59. T cell-mediated rejection of established tumors displays a varied requirement for perforin and IFN-γ expression which is not predicted by in vitro lytic capacity